Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
One good thing about the precision medicine approach/thought process is that the sponsor is expected to have a rational, fact based story to tell.
That compared to 20+ years of, let's take some population of known sick people and try XXXXZZZZXXX. And, If we try a big enough sample we should get some responses, and if we have to we can just expend the sample size. Hey, what could go wrong?
BTW, it looks like the breast cancer (very wealthy sponsor) Chemo people have hit a wall a lot like the Amyloid guys. Huh, well, "never mind the Chemo is not required, in fact it might be harmful" my emphasis. Maybe getting them to stand down was done a lot like the Amyloid guys.
Getting technical facts to support a thesis and then demonstrating efficacy is not an easy thing to do, but it will be a lot cheaper to do, faster to determine if/when real progress has been made and that it is sustainable. All of this comes from knowing what you are doing, vs shotgunning. And, when you are done you can actually use the results to learn something positive. Ain't science grand.
June 4, 2018
Developing Topic* abstract notifications sent via email (to the presenting author)
* Unless the research is considered to be late-breaking, Developing Topic abstracts will only be considered for poster presentations. The majority of Developing Topic presentations will be scheduled on Wednesday, July 25, 2018.
This text from AAIC site. Does anyone know how this process has worked in past? If AVXL to present will they do PR soon? Based on history...when will that happen?
Biostock....nicely done...thx.
http://www.anavex.com/wp-content/uploads/2018/05/Anavex-Presentation-May-2018-1.pdf
This new summary set is impressive. I would encourage anyone who has not yet done a quick scan to do so. Very, very impressive with convincing technical focus.
Special slides that got attention #13,29,33.
I also really like the theme connecting "precision medicine" to trial success rates. " Utilizing precision genetic medicine to treat severe neurological Disorders". This suggests a positive, direct link to knowledge being applied in targeting CNS disorders.
I know people at various regression levels who are experiencing CNS disorders (PD, MS, PD, other). Their families basically have come to live with the belief that nothing can be done. Anavex is giving (to me) a different kind of message which presents a refreshing, positive, precision science driven problem solving attitude. This is the opposite of the shotgun approach of the past XX years. Some days, attitude is all we can give and it matters a lot.
Read what they have done here also note the RS IND message.
Wrong again:
You need to go look at the accidental start of the era of antibiotics. What did happen? Why was it significant? Research Lab results Should have been ignored (according to your thinking), not supposed to happen. Old Pharma massive trial methods have proven nothing about discovery, reproducibility, yes. Predictions of certain failure are now recognized by even the BP thinkers as evidenced by their abandoned Amyloid trial methods. That is all they proved. BTW, these massive trials were carefully done according to methods you would no doubt find acceptable.
If one trial being conducted to evaluate safety resulted in some num. of patients(even one) actually reversing their dementia progression, then that result must be understood. According to your thinking these results mean nothing and must be ignored or somehow rationalized away. Had that happened w/Fleming and follow ups then antibiotics discoveries would have had to wait for some conventionally acceptable method. The very best researchers see things that should not have happened and then work to understand WHY. When a breakthrough happens (as possibly in A2-73 AU safety trials) ignoring the results that should not be there is not OK. You will soon see (AAIC-2018) the beginning of CNS disease treatment evolution.
You may also soon start to see the term "Binary Event" being used.
AVXL board challenge.
Answer this question w/facts:
Will ANAVEX be presenting as part of the upcoming July-2018 AAIC conference in Chicago? What will the title of the presentation be?
Note: AAIC says they will notify authors on June 4, 2018.
Prize to winner: A 50 round box of 0.45 ACP 230 gr.
Also saw that AAIC in Chicago in July will be sending notices to candidate authors on June 4 (next week-unless late breaking). If this is the conference Dr.M. keeps talking about then this could be an interesting period for changes. Sure am glad I do not own any of the amyloid plaque pushers stuff.
Let's not wait and do this again w/A2-73 etal
https://www.alz.org/aaic/abstracts/overview.asp
Other info....
Abstracts submitted Jan 29, 2018
Topic notice sent to presenting author June 4, 2018
Submissions Posters Only unless considered "late Breaking"
My own notice-observation: It looks like a majority of the topical papers/posters in 2017 mention or refer to Amyloid in the title. It will be interesting to see how many this year will include amyloid in title line.
jmv...thank you...AAIC -July-Chicago. Looking forward to news between now and then also. Anyone w/connections/sources should go on the point for us.
Likely upcoming conference news (AD/RS/PDD) A2-73?
What are the best thoughts on when/where Dr.M. will be doing next major conference A2-73 presentation?
What conference? Why? When? Where? Other?
It's always good to see Falconers posts.
Yup, we'll se I guess. There was shown a definite correlation between the drive to 2$ sp by posting irrational harassment here and the index date. In the future longs should remember this.
Right to try sounds plausible, in particular for CNS diseases as long as FDA controls/facility licenses (define, document and do) on where and how drugs are made are still effective.
http://thehill.com/policy/healthcare/388871-house-passes-right-to-try-sends-bill-to-trumps-desk
Bios...great post, thanks.
Roger that Talon.
After Looking closely at the Precision Medicine model w/new IND C/l requirements we can see that someone has been asleep in the tower for a long time. I am no expert but it is actually embarrassing when you look at how they processed the trials. It looks like they were watching for something to produce results which (I guess) could then be universally analyzed/applied to some population of AD patients. They literally had no idea what the treatment process would produce. They all did more or less the same thing. So, a lot of AD patients got "treated", some had brain bleed, some had swelling, other reactions but not one ever recovered.
I agree w/you that Dr.G. has at least stopped the train. How he did that so effectively and quietly w/o one word of wonder/question across so many massive news/political, Medical PR's, pharma organizations w/ so many people impacted is impressive. Only now, months after they called it off, are we seeing the occasional (saw one here yesterday) news piece on the failed Amyloid plaque thing. Wait a minute, we just spent a decade ++, spent Billions of $$$, sucked up FDA resources, BP talent/resources WW, thousands of AD patients/w/families (at least DEFCON 3) and all they have to say is ..."Never Mind". Part of learning involves failure analysis and discussing what DOES NOT WORK. It's called readiness training. Kicking ass works even in our new PC world.
Thanks again for your Air Force service, great pass.